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Abstract
Infection by Herpes Simplex Virus (HSV) type I and II cause a worldwide medical problems. HSV-I infections
are common in oral and perioral area. After primary infection, HSV becomes latent in the dorsal root ganglia and
recurrences are caused by many stimuli. Antiviral agents, prevention of transmission, suppression of recurrences
are current management of HSV infection. Objective: to discuss the management of Recurrent Intraoral Herpes
(RIH) infection. Case report: a 21 years old female patient came to hospital with irregular painful ulcers in her
mouth preceded by prodrome, followed with eruption and outbreak of vesicles. The first laboratory examination
confirmed high titer of reactive Immunoglobulin M (IgM) and IgG of anti HSV-I and HSV-II. She was diagnosed
to have RIH and treated with oral Acyclovir, multivitamins, immune stimulant and 0.2% chlorhexidine gargle
with good healing. Oral Valacyclovir was given after she had another recurrence, with the result of low episodes
of RIH and continuous titer improvement of reactive IgM and IgG of anti HSV-I and HSV-II. Conclusion: Oral
administration of Valacyclovir as a the oral prodrugs of Acyclovir is effective prophylactic and therapeutic option
with many advantages against HSV infection.

Abstrak
Penatalaksanaan infeksi Herpes berulang dengan valacyclovir. Infeksi Herpes Simplex Virus (HSV) tipe
I dan II mengakibatkan masalah kesehatan di seluruh dunia. Infeksi HSV-I sering mengenai daerah oral dan
perioral. Setelah infeksi primer, HSV menjadi laten di ganglion dorsal dan kambuh yang dipicu oleh berbagai
stimuli. Penatalaksanaan infeksi HSV adalah pemberian obat antivirus, pencegahan transimisi, penurunan tingkat
kekambuhan. Tujuan: membahas penatalaksanaan infeksi Herpes intraoral berulang. Laporan kasus: pasien
perempuan 21 tahun datang ke rumah sakit dengan ulser ireguler yang sakit di rongga mulut dan didahului oleh
gejala prodormal, timbulnya vesikel yang kemudian pecah. Hasil pemeriksaan laboratorium menunjukan titer
Imunoglobulin (Ig) M dan IgG anti HSV-I dan II yang reaktif. Acyclovir, multivitamin, stimulus imun, obat
kumur klorheksidin 0,2% diberikan dan pasien sembuh. Valacyclovir oral diberikan setelah pasien mengalami
kekambuhan dengan hasil penurunan tingkat rekurensi dan perbaikan titer reaktif IgM dan IgG anti HSV-I dan
II. Simpulan: valacyclovir oral sebagai obat prodrug Acyclovir yang efektif dalam terapi dan profilaksis dengan
berbagai keuntungan dalam mengobati infeksi HSV.
Key words: acyclovir, recurrent intraoral herpes, valacyclovir.

INTRODUCTION
The Herpes Simplex Viruses type I (HSV-I) and type
II (HSV-II) belong to the α – Herpesviridae and cause
a wide variety of clinical disorders.1-6 HSV infections
on humans are depending on the antigenic type of the
virus, site of inoculation and response of host immune.7
Recurrent intraoral herpes (RIH) infection is less
common in an immunocompetent host than Recurrent
Herpes Labialis (RHL). HSV-II infection is the most

prevalent cause of genital ulcerations of sexual nature
worldwide.1 The prevalence of HSV-I infection is 45%
to 98% of the world population and increases from
childhood to adulthood (70-80%) with seroprevalence
higher in lower socioeconomic groups. The HSV-II
seroprevalence has increased with 20% to 25% of US
adult have positive for HSV-II antibodies by the age
of 40.1,5
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P r i m a r y HSV-I (9 0 % of c a s e s) a nd HSV-I I
(occasionally) infection in human oral site is known
as primary herpetic gingivostomatitis and transmitted
by direct contact of mucous membranes or abraded
skin to the lesions or mucosal secretions of an active
primary or recurrent infection.1,8 HSV invades
epithelial cells and replicate intracellular at site of
primary exposure.1

Acyclovi r 200mg 5 ti mes a d ay for 10 d ays,
multivitamins, and 0.2% Chlorhexidine were given and
after 10 days, the ulcers were healed. We instructed the
patient to avoid sun exposure and use sunscreen. Two
months later, new vesicles were found on palatal, labial
mucosa, dorsum and lateral of the tongue. The patient’s
obedience to accomplish Acyclovir 5 times a day was
poor. Acyclovir was substituded with Valacyclovir
500mg twice a day for 15 days with the result no new
vesicles were erupted and the ulcers were healed.
Unfortunately the patient’s condition was exhausted
with sleep disturbance and new vesicles were found
on labial mucosa, dorsum and ventral and apex of the
tongue although the patient continued with Acyclovir
200 mg 5 times a day after Valacyclovir was run out.
She still consumed immune supplement 3 times a
day. The recurrence of HSV infection on lateral of
the tongue need to be treated again with Valacyclovir
500mg 3 times a day for two weeks with the result of no
new vesicles and ulcers. Episodes of recurrent of HSV
infection were decreased into 1 episode per month and
Acyclovir 200mg 3 times a day for 28 days was given
as prophylaxis treatment.

After primary infection, HSV ascends through the
periaxonal sheath of sensory nerves to the trigeminal,
cervical, lumbosacral or autonomic ganglia of the
host nervous system.1,6 Virus replicates and exists in
an immunologically shielded state until reactivation
is triggered spontaneously sometimes periodically
by different stimuli e.g exposure to ultraviolet
light, mechanical trauma, cosmetic disfigurement,
psychological distress, fever, dietary factors and
immunosuppression.1,3,5
Current management of HSV infection is to prevent
transmission, suppress of recurrance, attenuate
of clinical course, viral shedding complications,
palliation,avoidance of trigger factors and promotion
of healing. Antiviral agents ec Acyclovir and
Valacyclovir have been used in the treatment of HSV
infections.1-6

We performed Polymerase Chain Reaction (PCR) to
detect DNA of HSV on an lower labial mucosa ulcer
by swabbing vigorously using sterile cotton swab and
immediately sent the sample to the Departement of
Microbiology FKUI/RSCM using freezed container.
The result of PCR was negative with no finding of
DNA band of HSV. The immunology examination
of serum specimen confirmed seropositive 5.75x
increase in titer of IgM of anti HSV-I, 1.99x IgG
of anti HSV-I, 0.44x IgM of anti HSV-II, 0.94x
IgG of anti HSV-II (nor mal range titer: <0.9).
The haematology examination showed low count
of hematocrit (Ht), neutrophils and increased of
Erythrocyte Sedimentation Rate (ESR), monocyte,
blood creatinine.

In this case report, we discuss the management of a
21 years old immunocompetence female patient with
RIH who has frequent recurrent episodes. She was
treated with systemic Acyclovir, immune supplement
and then Acyclovir was replaced with Valacyclovir
and instruction to prevent transmission.

CASE REPORT
Female patient, 21 years old came to the Oral Medicine
Clinic RSCM with chief complaint of painful ulcers
in her mouth since 3 days ago. Previously, she had
prodrome symptoms followed by vesicles eruption
on labial, buccal mucosa, lateral and dorsum of
the tongue then ruptured in 1-2 days after forming
irregular pattern (Figure 1). Tenderness and swelling
of submandibular and servical lymph nodes were
documented. The patient always has a recurrent
oral ulcers before menstruation and often get cough,
flu, sleep disturbance. Previously in 2010, she had
Herpes infection according to the dermatologist.
The immunology examination of serum specimen
confirmed seropositive 2.46x increase in titer of
Immunoglobulin M (IgM) of anti HSV-I and 7.03x
titer of Immunoglobulin G (IgG) of anti HSV-I, 1.02x
titer of IgM of anti HSV-II and 1.72x titer of IgG of anti
HSV-II (normal range titer : <0.9). The haematology
examination showed low count of Hemoglobin (Hb)
and Eritrocyte Sedimentation Rate (ESR). She was
diagnosed to have RIH infection.

Because of low patient’s obedience and suspected
clinical resistance of Acyclovir, the medication was
substituted with Valacyclovir 500mg twice daily
for one month as prophylactic therapy for HSV
infection with under supervision for any side effects
of Valacyclovir. After a month of Valacyclovir, the
immunology examination confirmed seropositive
2.74x increase in titer of IgM of anti HSV-I, 4.65x
IgG of anti HSV-I, 0.66x IgM of anti HSV-II,
0.93x IgG of anti HSV-II (normal range titer :<0.9).
The haematology examination showed low count
of Hematocrit (Ht), neutrophils and increased of
Eritrocyte Sedimentation Rate (ESR), while the
screening test for HIV antibody was negative, CD4
count was 753cells/µL (normal range 410 – 1590),
CD8 count was 683cells/µL (normal range 190-1140).
Figure 2.
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Figure 1. Painful multiple irreguler ulcers surrounded by erythematous area on various areas of oral mucosa. (A-E)
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Figure 2. Ulcerated oral mucosa healed after treatment with two weeks of 500mg Valacyclovir (A-D).

DISCUSSION
Recurrence of HSV infection is a reactivation of HSV
lead to asymptomatic viral shedding; recrudescence
is a viral reactivation with clinical manifestations.
Recurrence is triggered by internal and external trigger
and leading to proliferative state.1,3 In our patient,
we suggest that physchological stress, fatigue and
menstruation as triggering factors of recrudescence of
HSV inffection. Infection in the mouth is less common
than herpes labialis and unusual in otherwise healthy
persons.4
The seropositive of IgM and IgG antibodies to HSV-I
and HSV-II in our patient can be a marker of HSV-II

induced recurrent orofacial disease although it is rare.1
Although presence of IgG doesn’t indicate reinfection,
recurrent infection or immunity. Immunoglobulin M
can be demonstrated for weeks after primary infection.9
Reactivation are less frequent after the age of 35 and
contrary more frequent before the age of 35 as it happens
in our patient. Recurrent episodes are milder and shorter
in duration with minimal systemic involvement. Oedem
on upper lips in our patient known as RHL which
typically affects the outer vermilion border and adjacent
cutaneous region. Recurrent Intraoral Herpes typically
located on tongue and keratinezed mucosa of the hard
palate and attached gingiva.1
29
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Realtime amplification techniques (PCR) is a high
specifity and sensitivity test which can detect small
piece of DNA of the virus and low levels of HSV
shedding. Because of the rapid development of the
vesicle stage (<12 h) and the fast decrease in detectable
virus after 48 h may be the reasons why the result is
negative although viral shedding still continues for
3 to 8 days after the lesions have resolved.1,3,9 Many
antivirus drugs have been used to overcome and
inhibit the viral DNA synthesis. It can be achieved by
a variety of process: direct inhibition of the viral DNA
polymerase by competition with the natural nucleoside
triphosphate (dGTP in the case of the triphosphate
of Acyclovir, ganciclovir and penciclovir), chain
termination of the growing viral DNA (acyclovir)
or DNA strand breakage after incorporation of the
unnatural nucleotide in the viral DNA.1-4

(less than 3%) and the incidence of resistant HSVI strains remains low (0.5% in immunocompetent
patients).2,5 We suspected our patient had clinically
resistant HSV to Acyclovir because Acyclovir did not
reduce the vesicles formation, severity and duration of
the symptoms. These may be caused by one or more
of the following mechanisms: complete deficiency in
viral TK activity, decreased production of viral TK
(TK low producer virus), viral TK protein with altered
substrate specificity (Tk altered virus; the enzyme is
able to phosphorylate thymidine not Acyclovir), or a
viral DNA polymerase with altered substrate specificity (DNA pol altered). A TK-deficient phenotype has
been observed in 95% of Acyclovir-resistant isolates.
However, several reports have demonstrated that at
least some TK activity is needed for HSV reactivation
from latency in neural ganglia.4

Acyclovir {9-[(2-hydroxyethoxy)methyl)guanine]}
is a nucleoside analogue of guanosine and by
phosphorylation transformed its active state by viral
thymidine kinase (TK). The affinity of Acyclovir for
herpesvirus encoded TK is approximately 200 times
greater than for human TK, thus phosphorylation of
Acyclovir by the human enzyme occurs at a negligible
rate. This selective affinity results in the activation
and concentration of Acyclovir in virus-infected
cells. 4 Following phosphorylation to Acyclovir
monophosphate (aciclo-GMP), normal host cellular
enzymes catalyse the sequential phosphorylation to
Acyclovir diphosphate (aciclo-GDP) and Acyclovir
triphosphate (aciclo-GTP); this nucleoside triphosphate
is a potent inhibitor of viral DNA synthesis as it
competes with viral nucleotides for incorporation into
viral DNA. Once incorporated, it terminates DNA
chain synthesis (and thus inhibits viral replication),
giving rise to nonfunctional DNA strands.4

Valacyclovir is the L-valine ester prodrug of Acyclovir
and has the same mechanism of action, requiring Tk
dependent conversion to the monophosphate form.
Valacyclovir is absorbed from the gastrointestinal
tract and converted to Acyclovir by intestinal and
hepatic first pass metabolism. Sixty-three percent of
the Valacyclovir oral dose is absorbed and converted
to Acyclovir, compared with the 15–21% absorption of
orally administered Acyclovir. Acyclovir is detected
in plasma 15 min after Valacyclovir administration.
Thus, Valacyclovir is increasing the limited oral
bioavailability of Acyclovir three to f ive-fold.
Valacyclovir has a safety profile similar to Acyclovir,
with mild neurotoxicity and severe nephrotoxicity in
animals at single doses of 1 and 2–5g/kg) respectively.4
Nowadays, systemic Valacyclovir is effective for the
treatment of herpes labialis especially when started
during the prodrome of the disease eventhough the
optimal dose is still unkown. It has more convenient
dosing regimen (once, twice or three times daily
compared with five times daily for Acyclovir) and it is
likely that Valacyclovir will finally replace Acyclovir
in the oral treatment of HSV or VZV infections in
immunocompetent persons.7 For these advantages, we
choose Valacyclovir for the prophylactic therapy of
recurrent HSV infection with supportive treatment such
as immune supplement, topical 0.2% chlorhexidine.
Chlorhexidine digluconate is effective against grampositive organisms, gram-negative organisms, aerobes,
facultative anaerobes, and yeast.11 We also gave
instruction to take good rest,avoid sun exposure and
prevent cross infection by avoid kissing anyone, share
kitchen or bathroom utensils.3

The antiviral activity of Acyclovir may be effective in
reducing the duration of symptoms of recurrent HSV-1
infection, although the optimal timing and dose of the
treatment are uncertain. Intravenous Acyclovir will
still the first line for the management of severe cases
which require hospitalization such as neonatal herpes,
HSV encephalitis or disseminated HSV infections in
immunocompromised hosts 3,4
The prophylactic oral Acyclovir with adjustment to
the many situations can reduce the frequency and
severity of recurrent attack of herpetic infection in
immunocompromised patients, although the dose,
optimal timing and duration of treatment is uncertain
and can vary in different situations.4 Titer of IgM, IgG
of anti HSV-I and HSV-II from the 1st and 2nd result
showed decreased titer count because of the use of
Acyclovir prophylactic therapy for 1 month.9

The adverse events and drug-related adverse events
of Acyclovir and Valacyclovir are headache, nausea,
diarrhoea, nephrotoxicityand a small number of cases
of rash, hallucinations, confusion, dyspepsia, dry mouth
and flatulence.4 It is important to follow up the patient’s
condition when long term or prophylactic therapy with
the laboratory examination of kidney and liver function.

Herpes simplex virus type 1 infection in immunocompetent patients usually requires short-term antiviral
therapy, thus HSV drug resistance is unlikely to arise
30
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CONCLUSION
Current therapeutic modalities include preventive
measures, non specific immune stimulation, topical
applications of antiseptic, antiviral agents. Oral
administration of VCV as a the oral prodrug of ACV
is effective prophylactic and therapeutic option with
many advantages against HSV infection and nowadays
is replacing ACV.
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